Abstract: Objective To compare the efficacy and toxicity of concurrent nedaplatin or cisplatinbased chemoradiation for locally advanced cervical cancer. Methods From August 2009 to August 2011，86 cases of cervical cancer pathologically proved from stage ⅡB to stage ⅣA were randomly divided into nedaplatin group and cisplatin group. Patients in both groups were received intensity-modulated radiation of pelvic cavity and brachytherapy. The total dose of gross tumor volume was 56Gy／28f，for clinical target volume 50Gy／28f in IMRT and 25.30Gy in brachytherapy. Patients in nedaplatin／cisplatin group received weekly nedaplatin／cisplatin 25mg／m2began at the d1 of radiotherapy for 5 to 6 times totally. ResultsThe overall response rate of two groups was both 100.0％，and the CR rate（CRR）in nedaplatin group and cisplatin group was 89.1％ and 87.5％ respectively without significant difference. As to the side effects，the incidence of anorexia，nausea，vomiting and loss of body weight in nedaplatin group were less than those in cisplatin group with significant difference，while thrombocytopenia and leukopenia was a little higher than that in cisplatin group but without significant difference. The incidence of acute cystitis and rectitis above stage Ⅱ was low. Conclusion The efficacy of concurrent nedaplatin or cisplatin based chemoradiation for locally advanced cervical cancer is similar，however，the nedaplatin group has a lower rate of nausea，vomiting and a better tolerance than the cisplatin group.